Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3853-3862

  Adachi, Masaaki ^a   Zhang, YuBin ^a   Zhao, Xudong ^a   Minami, Takae ^a   Kawamura, Rina ^a   Hinoda, Yuji ^b   Imai, Kohzoh ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 CARBOXYCINNAMIC ACID BISHYDROXAMIDE; 5(6) CARBOXY 2',7' DICHLORODIHYDROFLUORESCEIN DIACETATE; 8 HYDROXYDEOXYGUANOSINE; ACETOACETIC ACID DERIVATIVE; ACETYLCYSTEINE; BIM PROTEIN; BORTEZOMIB; CASPASE 3; CELL CYCLE PROTEIN; CHLORINE DERIVATIVE; CYCLODEPSIPEPTIDE; DNA FRAGMENT; FLUORESCEIN DERIVATIVE; FLUOROURACIL; FR 901228; H2 ANTIGEN; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE P38; N BENZYLOXYCARBONYLISOLEUCYLGLUTAMYL (O TERT BUTYL)ALANYLLEUCINAL; PHOSPHATIDYLSERINE; PROTEASOME INHIBITOR; REACTIVE OXYGEN METABOLITE; SCAVENGER; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; ANNEXIN A5; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CASPASE 3; CASPASES; CELL LINE, TUMOR; CINNAMATES; COLONIC NEOPLASMS; DEPSIPEPTIDES; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; FREE RADICALS; GASTROINTESTINAL NEOPLASMS; HISTONES; HUMANS; MICROSCOPY, CONFOCAL; OLIGOPEPTIDES; OXYGEN; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 2542616162     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0806     Document Type: Article

References (40)

1. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997;9:788-99.
2. Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat Immunol 2002;3:20-6.
3. Yang Y, Yu X. Regulation of apoptosis: the ubiquitous way. FASEB J 2003;17:790-9.
4. McBride WH, Iwamoto KS, Syljuasen R, Pervan M, Pajonk F. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 2003;22:5755-73.
5. Fuchs SY, Fried VA, Ronai Z. Stress-activated kinases regulate protein stability. Oncogene 1998;17:1483-90.
6. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994;13:5433-41.
7. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071-6.
8. Myung J, Kim KB, Crews CM. The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 2001;21:245-73.
9. Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-9.
10. Barlogie B, Shaughnessy JD, Tricot G, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
11. Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003;9:1145-54.
12. Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 2002;1:841-9.
13. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
14. Yoshida M, Horinouchi S. Trichostatin and leptomycin. Inhibition of histone deacetylation and signal-dependent nuclear export. Ann N Y Acad Sci 1999;886:23-36.
15. Nervi C, Borello U, Fazi F, et al. Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res 2001;61:1247-9.
16. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (Bethesda) 2000;92:1210-6.
17. Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anti-Cancer Drugs 2002;13:1-13.
18. Ju R, Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 2003;63:2891-7.
19. Glick RD, Swendeman SL, Coffey DC, et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res 1999;59:4392-9.
20. Furumai R, Matsuyama A, Kobashi N, et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002;62:4916-21.
21. O'Connor L, Strasser A, O'Reilly LA, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998;17:384-95.
22. De Flora S, Izzotti A, D'Agostini F, Balansky RM. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis (Lond) 2001;22:999-1013.
23. Yawata A, Adachi M, Okuda H, et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene 1998;16:2681-6.
24. Koyama Y, Adachi M, Sekiya M, Takekawa M, Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 2002;96:1490-5.
25. Ju R, Muller MT. Histone deacetylase inhibitors activate p21(WAF1) expression via ATM. Cancer Res 2003;63:2891-7.
26. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002;3:420-5.
27. Goedert M, Cuenda A, Craxton M, Jakes R, Cohen P. Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases. EMBO J 1997;16:3563-71.
28. Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003;2:151-63.
29. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 2003;278:33714-23.
30. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003;63: 3637-45.
31. Paull TT, Rogakou EP, Yamazaki V, et al. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000;10:886-95.
32. Abu-Shakra A, Zeiger E. Formation of 8-hydroxy-2′-deoxyguanosine following treatment of 2′-deoxyguanosine or DNA by hydrogen peroxide or glutathione. Mutat Res 1997;390:45-50.
33. Toyokuni S, Tanaka T, Hattori Y, et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Investig 1997;76:365-74.
34. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28.
35. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8.
36. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 2002;97:290-6.
37. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
38. Yu C, Rahmani M, Conrad D, et al. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood 2003;102:3765-74.
39. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
40. Petrie K, Guidez F, Howell L, et al. The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 2003;278:16059-72.